

Emilio Iannitto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4810719/publications.pdf>

Version: 2024-02-01

22
papers

1,451
citations

567144

15
h-index

752573

20
g-index

22
all docs

22
docs citations

22
times ranked

1730
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. <i>Blood</i> , 2003, 102, 996-999.	0.6	282
2	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , 2006, 107, 4643-4649.	0.6	217
3	Splenic marginal zone lymphoma. <i>Blood</i> , 2003, 101, 2464-2472.	0.6	172
4	Gamma-delta T-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 707-717.	12.5	152
5	Hepatitis B virus reactivation and alemtuzumab therapy. <i>European Journal of Haematology</i> , 2005, 74, 254-258.	1.1	115
6	How I diagnose and treat splenic lymphomas. <i>Blood</i> , 2011, 117, 2585-2595.	0.6	91
7	Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. <i>British Journal of Haematology</i> , 2012, 159, 164-171.	1.2	81
8	Splenic marginal zone lymphoma with or without villous lymphocytes. <i>Cancer</i> , 2004, 101, 2050-2057.	2.0	67
9	Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 160, 207-215.	1.2	57
10	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018, 183, 755-765.	1.2	41
11	Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. <i>Leukemia and Lymphoma</i> , 2014, 55, 929-931.	0.6	40
12	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. <i>Blood</i> , 2014, 123, 1836-1849.	0.6	37
13	Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. <i>European Journal of Haematology</i> , 2005, 75, 130-135.	1.1	25
14	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3281-3287.	0.6	25
15	Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. <i>The Hematology Journal</i> , 2004, 5, 530-533.	2.0	20
16	Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma. <i>European Journal of Haematology</i> , 2006, 76, 134-140.	1.1	14
17	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. <i>European Journal of Haematology</i> , 2020, 104, 581-587.	1.1	10
18	Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglobulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells. <i>Blood</i> , 2010, 116, 634-634.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial. Blood, 2010, 116, 1360-1360.	0.6	2
20	Hepatitis B Virus Reactivation and Alemtuzumab Therapy.. Blood, 2004, 104, 4816-4816.	0.6	1
21	Splenic Marginal Zone Lymphoma. Hematologic Malignancies, 2021, , 127-142.	0.2	0
22	Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).. Blood, 2004, 104, 4536-4536.	0.6	0